Literature DB >> 1995974

Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures.

S S Dikmen1, N R Temkin, B Miller, J Machamer, H R Winn.   

Abstract

In order to determine potential negative neurobehavioral effects of phenytoin given to prevent the development of posttraumatic seizures, 244 subjects were randomized to phenytoin or placebo. They received neurobehavioral assessments at 1 and 12 months postinjury while receiving their assigned drug and at 24 months while receiving no drugs. In the severely injured, phenytoin significantly impaired performance at 1 month. No significant differences were found as a function of phenytoin in the moderately injured patients at 1 month or in either severity group at 1 year. Patients who stopped receiving phenytoin according to protocol between 1 and 2 years improved more than corresponding placebo cases on several measures. We conclude that phenytoin has negative cognitive effects. This, combined with lack of evidence for its effectiveness in preventing posttraumatic seizures beyond the first week, raises questions regarding its use for long-term prophylaxis. Our findings do not negate phenytoin's proven efficacy in controlling established seizures nor do they indicate that its cognitive effects are worse than other anticonvulsant drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995974

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  34 in total

1.  Head injury for neurologists.

Authors:  Richard Greenwood
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

2.  Prophylaxis and treatment of posttraumatic epilepsy with phenytoin.

Authors:  T Massagli
Journal:  West J Med       Date:  1992-12

Review 3.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

Review 4.  Elucidating opportunities and pitfalls in the treatment of experimental traumatic brain injury to optimize and facilitate clinical translation.

Authors:  Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Biobehav Rev       Date:  2017-05-30       Impact factor: 8.989

5.  Variation in Anticonvulsant Selection and Electroencephalographic Monitoring Following Severe Traumatic Brain Injury in Children-Understanding Resource Availability in Sites Participating in a Comparative Effectiveness Study.

Authors:  Jonathan E Kurz; Samuel M Poloyac; Nicholas S Abend; Anthony Fabio; Michael J Bell; Mark S Wainwright
Journal:  Pediatr Crit Care Med       Date:  2016-07       Impact factor: 3.624

Review 6.  Pharmacological prophylaxis of post-traumatic epilepsy.

Authors:  A Iudice; L Murri
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

7.  Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the Theiler's murine encephalomyelitis virus mouse model.

Authors:  Melissa L Barker-Haliski; E Jill Dahle; Taylor D Heck; Timothy H Pruess; Fabiola Vanegas; Karen S Wilcox; H Steve White
Journal:  J Pharmacol Exp Ther       Date:  2015-03-09       Impact factor: 4.030

8.  Measuring outcome in traumatic brain injury treatment trials: recommendations from the traumatic brain injury clinical trials network.

Authors:  Emilia Bagiella; Thomas A Novack; Beth Ansel; Ramon Diaz-Arrastia; Sureyya Dikmen; Tessa Hart; Nancy Temkin
Journal:  J Head Trauma Rehabil       Date:  2010 Sep-Oct       Impact factor: 2.710

Review 9.  Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation.

Authors:  Alexandra N Garcia; Mansi A Shah; C Edward Dixon; Amy K Wagner; Anthony E Kline
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

Review 10.  Anti-epileptogenic clinical trial designs in epilepsy: issues and options.

Authors:  Dieter Schmidt; Daniel Friedman; Marc A Dichter
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.